Trial Profile
A Phase 3 Randomized, Double-Blind, Placebo- and Oxycodone-Controlled, Multicenter Study of the Efficacy and Safety of Tanezumab in Patients With Osteoarthritis of the Knee or Hip.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary) ; Oxycodone
- Indications Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database.
- 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 16 Dec 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.